Design of an epitope-based peptide vaccine against Cryptococcus neoformans

Abstract

IntroductionThis study aimed to design an immunogenic epitope for Cryptococcus neoformans the etiological agent of cryptococcosis using in silico simulations, for epitope prediction, we selected the mannoprotein antigen MP88 which its known to induce protective immunity.\n\nMaterial & methodA total of 39 sequences of MP88 protein with length 378 amino acids were retrieved from the National Center for Biotechnology Information database (NCBI) in the FASTA format were used to predict antigenic B-cell and T cell epitopes via different bioinformatics tools at Immune Epitope Database and Analysis Resource (IEDB). The tertiary structure prediction of MP88 was created in RaptorX, and visualized by UCSF Chimera software.\n\nResultA Conserved B-cell epitopes AYSTPA, AYSTPAS, PASSNCK, and DSAYPP have displayed the most promising B cell epitopes. While the YMAADQFCL, VSYEEWMNY and FQQRYTGTF they represent the best candidates T-cell conserved epitopes, the 9-mer epitope YMAADQFCL display the greater interact with 9 MHC-I alleles and HLA-A*02:01 alleles have the best interaction with an epitope. The VSYEEWMNY and FQQRYTGTF they are non-allergen while YMAADQFCL was an allergen. For MHC class II peptide binding prediction, the YARLLSLNA, ISYGTAMAV and INQTSYARL represent the most Three highly binding affinity core epitopes. The core epitope INQTSYARL was found to interact with 14 MHC-II. The allergenicity prediction reveals ISYGTAMAV, INQTSYARL were non-allergen and YARLLSLNA was an allergen. Regarding population coverage the YMAADQFCL exhibit, a higher percentage among the world (69.75%) and the average population coverage was 93.01%. In MHC-II, ISYGTAMAV epitope reveal a higher percentage (74.39%) and the average population coverage was (81.94%). This successfully designed a peptide vaccine against Cryptococcus neoformans open up a new horizon in Cryptococcus neoformans research; the results require validation by in vitro and in vivo experiments.